0001104659-20-140992.txt : 20201231 0001104659-20-140992.hdr.sgml : 20201231 20201231163027 ACCESSION NUMBER: 0001104659-20-140992 CONFORMED SUBMISSION TYPE: 5 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20201231 DATE AS OF CHANGE: 20201231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISS MICHAEL S CENTRAL INDEX KEY: 0001038977 FILING VALUES: FORM TYPE: 5 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 201429132 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 5 1 tm2039708-1_form5.xml OWNERSHIP DOCUMENT X0306 5 2020-12-31 0 0 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001038977 WEISS MICHAEL S 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 1 1 0 0 CEO and President COMMON STOCK 2020-09-10 5 G 0 525000 0 D 13909214 D COMMON STOCK 2020-09-25 5 G 0 2500 0 D 13906714 D COMMON STOCK 2020-12-15 5 G 0 834877 0 D 13071837 D COMMON STOCK 2020-12-15 5 G 0 1700 0 D 13070137 D COMMON STOCK 2020-12-15 5 G 0 200 0 D 13069937 D COMMON STOCK 2020-12-22 5 G 0 200 0 D 13069737 D COMMON STOCK 2020-12-28 5 G 0 1000 0 D 13068737 D COMMON STOCK 2020-12-28 5 G 0 655 0 D 13068082 I See Note 3 Reflects the transfer of shares of TG Therapeutics stock to the Weiss Family and Descendants Trust. Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. /s/ Michael Weiss 2020-12-31